Keyphrases
Mantle Cell Lymphoma
99%
Rituximab
78%
Follicular Lymphoma
60%
Diffuse Large B-cell Lymphoma (DLBCL)
58%
Relapsed or Refractory
56%
Progression-free Survival
48%
Overall Survival
46%
Lymphoma
32%
Doxorubicin
31%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
31%
Maintenance Rituximab
29%
Prednisone
28%
Phase II Study
28%
Lymphoma Patients
27%
Chronic Lymphocytic Leukemia
27%
Clinical Trials
27%
Bendamustine
26%
Complete Response
25%
Non-Hodgkin Lymphoma
24%
Cyclophosphamide
23%
Bortezomib
22%
Hodgkin Lymphoma
21%
Bendamustine-rituximab
21%
Overall Response Rate
20%
Indolent non-Hodgkin Lymphoma
20%
Wisconsin
18%
Confidence Interval
18%
R-CHOP
18%
Chemotherapy
17%
Oncological Networks
16%
Initial Treatment
15%
Eastern Cooperative Oncology Group
15%
Network Studies
15%
High Risk
14%
Brentuximab Vedotin
14%
Lenalidomide
14%
Clinical Outcomes
13%
Indolent Lymphoma
13%
Low Tumor Burden
12%
Peripheral T-cell Lymphoma
12%
Frontline Therapy
12%
Duration of Response
12%
Older Patients
11%
Ibrutinib
11%
Newly Diagnosed
11%
Hazard Ratio
11%
International Prognostic Index
11%
Chemoimmunotherapy
11%
Recent Advances
11%
Previously Untreated
11%
Medicine and Dentistry
Mantle Cell Lymphoma
84%
Rituximab
80%
Diffuse Large B-Cell Lymphoma
53%
Overall Survival
50%
Non-Hodgkin Lymphoma
47%
Progression Free Survival
45%
Follicular Lymphoma
41%
Diseases
38%
Oncology
37%
Clinical Trial
36%
Neoplasm
30%
Bendamustine
26%
Hodgkin's Lymphoma
26%
Doxorubicin
24%
B-Cell Chronic Lymphocytic Leukemia
22%
Vincristine
21%
B Cell
20%
Cyclophosphamide
19%
Prednisone
18%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
15%
Arm
15%
Lymphocytic Lymphoma
15%
B-Cell Lymphoma
13%
Adriamycin Bleomycin Vinblastine Dacarbazine
13%
Bortezomib
12%
Transplantation
12%
Peripheral T-Cell Lymphoma
12%
Malignant Neoplasm
12%
Positron Emission Tomography
12%
Biological Marker
11%
Ibrutinib
11%
Stem Cell Transplant
11%
Lenalidomide
11%
Brentuximab Vedotin
10%
Classical Hodgkin Lymphoma
10%
Chemoimmunotherapy
9%
Drug Megadose
9%
Cytarabine
9%
Adverse Event
9%
Hematopoietic Cell
9%
Autologous Stem Cell Transplantation
9%
Phosphoinositide 3-Kinase
9%
Cohort Analysis
8%
Hazard Ratio
8%
MALT Lymphoma
8%
Cell Transplantation
8%
Electrocorticography
8%
Cancer
8%
Hematologic Malignancy
8%
T Cell
7%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
100%
Mantle Cell Lymphoma
71%
Nonhodgkin Lymphoma
52%
Follicular Lymphoma
52%
Diffuse Large B Cell Lymphoma
45%
Bendamustine
39%
Progression Free Survival
39%
Diseases
37%
Overall Survival
37%
Cyclophosphamide
28%
Vincristine
28%
Chemotherapy
26%
Doxorubicin
26%
Clinical Trial
25%
Prednisone
24%
Chronic Lymphatic Leukemia
23%
Neoplasm
23%
Bortezomib
19%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
15%
Remission
15%
Adverse Event
12%
Hodgkin Disease
12%
Lymphocytic Lymphoma
12%
Malignant Neoplasm
11%
Lenalidomide
11%
Phosphatidylinositol 3 Kinase
10%
Etoposide
10%
Ibrutinib
8%
Neutropenia
8%
B Cell Lymphoma
8%
Ibritumomab Tiuxetan
8%
Event Free Survival
7%
Idelalisib
7%
Venetoclax
7%
Loncastuximab Tesirine
7%
Pharmacokinetics
7%
Peripheral T Cell Lymphoma
6%
Tolerability
6%
Zanubrutinib
6%
Yttrium 90
6%
Duvelisib
6%
Survival Rate
6%
Combination Therapy
6%
Hematologic Malignancy
6%
Minimal Residual Disease
6%
Methotrexate
5%
Diarrhea
5%
Brentuximab Vedotin
5%
Biological Marker
5%
Bruton Tyrosine Kinase
5%